Caladrix
- Biotech or pharma, therapeutic R&D
Caladrix Inc. was founded in 2025 to address the urgent unmet need in Alzheimer’s disease and related neurodegenerative disorders. Headquartered in Palo Alto, with clinical operations in Melbourne, Australia, and development research in Germany, Caladrix is pioneering a new therapeutic paradigm centered on activating the brain’s natural clearance pathways.
The company’s mission is to deliver transformative, non-immunologic treatments that work in harmony with the brain’s innate biology, leveraging validated transporter biology and scalable oral delivery.
Caladrix’s strategy combines scientific innovation, strategic partnerships, and capital efficiency to advance from preclinical discovery to accelerate our lead clinical candidate through global clinical development.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}